Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia 24Breast Neoplasms 20Lymphoma 9Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia, Myeloid, Acute 6Precancerous Conditions 5Multiple Myeloma 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Congenital Abnormalities 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Colorectal Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma Of Esophagus 4Wilms Tumor 3Rectal Neoplasms 3Prostatic Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neuroblastoma 3

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Microarray Analysis × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡